Rakuten Aspyrian Stock
Tumor-targeted precision therapies
Sign up today and learn more about Rakuten Aspyrian Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Rakuten Aspyrian Stock
Rakuten Aspyrian is a privately funded clinical stage biotechnology company developing tumor-targeted precision therapies based on its proprietary platform Photoimmunotherapy. Photoimmunotherapy combines key advantages of antibody-mediated targeting of the cancer cells to achieve high tumor specificity, together with laser-activation of a biophysical mechanism that induces rapid cancer cell death with precision. Treatments with the Photoimmunotherapy platform lead to targeted and rapid tumor cell death by necrosis, with minimal effects on normal tissue. Rakuten Aspyrian is studying Photoimmunotherapy for use as a monotherapy and in combination with other drugs. Founded in 2013, the company is based in San Diego, California.
Chief Executive Officer
COO & President
Chief Technical Officer
Carlos A. Garcia
Finances and Operations
Head of Chemistry